CD274 and neoplasm: Several tumor biomarkers, including Programmed Death Ligand 1 (PD-L1) immunohistochemistry and RNA gene expression profile (GEP) IFN-gamma cytolytic signatures, have been reported to predict the clinical response to immune checkpoint blockade immunotherapy, especially to anti- PD-L1 and anti-Programmed Death 1 (PD-1) immunotherapies.